Cancer immunotherapy

• US 7,338,929 B2
• Filed: 03/22/2002
• Issued: 03/04/2008
• Est. Priority Date: 02/08/2000
• Status: Expired due to Term

• Current Assignee: Penn State Research Foundation
• Original Assignee: Penn State Research Foundation
• Inventors: Debinski, Waldemar, Christensen, Neil, Mintz, Akiva
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Halvorson; Mark
• Application Number:
  US10/104,408
• Publication Number:
  US 20020182219A1
• Time in Patent Office: 2,174 Days
• Field of Search: 424/184.1, 514/1
• US Class Current: 424/185.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/001184 Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.

Claims

1. A method for stimulating an immune response against IL-13Rα

2 in a subject having glioma cells expressing IL-13Rα

2, the method comprising the steps of;

(a) formulating a composition outside of the subject, the composition comprising an agent that can stimulate an immune response against IL-13Rα

2 when administered to a subject having glioma cells expressing IL-13Rα

2;

wherein the agent that can stimulate an immune response against IL-13Rα

2 is a protein comprising the amino acid sequence of SEQ ID NO;

1 or a protein fragment thereof; and

,

(b) administering the composition to the subject in an amount sufficient to stimulate an immune response against IL-13Rα

2 in the subject.

2. The method of claim 1, wherein the composition further comprises an adjuvant.

3. The method of claim 2, wherein the adjuvant comprises a substance selected from the group consisting of:

an aluminum salt;

an oil-in-water emulsion;

a composition comprising saponin;

a composition comprising a bacterial protein; and

a cytokine.

4. The method of claim 2, wherein step (b) of administering the composition to the subject in an amount sufficient to stimulate an immune response against IL-13Rα

2 in the subject comprises administering the composition in at least a first dose and a second dose, wherein said first dose is administered to the subject at least 24 hours before said second dose is administered to the subject.

5. The method of claim 1, wherein the subject is a human being.

6. The method of claim 1, wherein the agent comprises amino acids 27-343 of SEQ ID NO:

1.